RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Parent Weekly Individual Telephone Support for Obesity

This study wants to determine the most effective family-centered intervention (FCI) for weight loss and obesity prevention in Hispanic families. FCI is a type of program that involves family (such as parents and caregivers) supporting their children to promote healthy habits.

Official registry: https://clinicaltrials.gov/study/NCT07144800 · Memorial Sloan Kettering Cancer Center · enrollment listed as 1,319

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Parent Weekly Individual Telephone Support, Child Education, or Parent Initial Counseling. The registry lists allocation as randomized. This study wants to determine the most effective family-centered intervention (FCI) for weight loss and obesity prevention in Hispanic families.

They plan to enroll about 1,319 people at New York. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)

Interventions: Parent Weekly Individual Telephone Support, Child Education, Parent Initial Counseling, Parent Monthly Group Support

Primary outcome (registry wording): Percentage weight loss from baseline among participants

Who it is for (from inclusion criteria)

Ages 18 Years to any
Age \>= 18 years (per self-report)
Self-identifies as Hispanic/Latino (per self-report)
Seeking, or has used, services at the VDS or MHU (per self-report)
Is the parent or primary caregiver for at least one child aged 8-12 living in their household (per self-report)
Screens as obese (body-mass index (BMI) \> 30 kg/m2) or overweight (body-mass index (BMI) of 25 - 29.9 kg/m2) (per height and weight measurement in person or per self-report)
Owns a cell phone capable of receiving text messages (per self-report)
Owns an internet connected device (e.g. cell phone, tablet, etc.) capable of conducting videoconference calls (per self-report)

Who the registry excludes

Is pregnant or might be pregnant (per self-report)
Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with hypertension and diabetes mellitus may still participate) that may affect diet and study participation (per self-report)
Has dietary restrictions, i.e. liquid diet, that may affect diet and study participation (per self-report)
Has a household member who has already participated or agreed to participate in this study program (per self-report)
Prior participation in one of our preliminary studies, e.g., COMIDA, SANOS, Family COMIDA (per self-report) and any related focus groups
Works for or with the VDS or MHU (per self-report)
Phase 2 (parent participant)

Public study contact (from the registry)

Jennifer Leng, MD, MPH

646-888-8057

lengj@mskcc.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseBuffalo, New York

Blood Collection Biorepository for Liver Disease Research

The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.

NCT03025074 · Official ClinicalTrials.gov record · State University of New York at Buffalo

RecruitingNot a traditional drug phaseMontreal, Quebec

Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

FAQ about this NCT record

Is NCT07144800 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07144800?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07144800?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary